EXHIBIT 99.1 Endovia Health Sciences Closes Initial $500,000 Financing to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways Initial funding represents first tranche of previously announced $1 million C/M Capital commitment supporting CannEpil® development and commercialization Financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines FORT LAUDERDALE, Fla. - September 22, 2026 - Endovia Health Sciences, Inc. (NYSE American: EDVA) (“Endovia” or the “Company”), a cannabinoid health sciences company, today announced that it has closed $500,000 of initial secured convertible debt funding from C/M Capital Master Fund, LP (“C/M Capital”), representing the first tranche of the aggregate $1 million investment commitment previously announced in connection with the Company’s exclusive global licensing agreement for CannEpil® with Argent BioPharma Limited. The financing provides additional capital to advance the development and commercialization of CannEpil®, including Endovia’s U.S. FDA-regulated veterinary development program and international commercialization…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
Endovia Health Sciences, Inc.
EDVANYSE_AMERICANEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On September 22, 2026, Endovia Health Sciences, Inc. (the “Company”) issued a press release announcing certain developments. A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.…
Company context
Splash is a Nevada corporation that was historically seeking to identify, acquire, and build early stage or under-valued beverage brands that have strong growth potential within its distribution system. During the current fiscal year beginning January 1, 2026, Splash has moved away from beverages and is focusing on the cannabinoid and wellness economy businesses.
Current securities
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On September 22, 2026, Endovia Health Sciences, Inc.
(the “Company”) issued a press release announcing certain developments. A copy of the press release is furnished as Exhibit
99.1 of this Current Report on Form 8-K.
The information in this Item 7.01 (including Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of
the Company under the Securities Act of 1933 or the Exchange Act.